nimodipine has been researched along with Parkinson Disease in 5 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Excerpt | Relevance | Reference |
---|---|---|
"Nimodipine treatment in this model did not impact dopamine graft survival but allowed for increased graft reinnervation of striatum." | 1.36 | Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. ( Collier, TJ; Levine, ND; O'Malley, JA; Soderstrom, KE; Sortwell, CE; Steece-Collier, K, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ji, B | 1 |
Wang, M | 1 |
Gao, D | 1 |
Xing, S | 1 |
Li, L | 1 |
Liu, L | 1 |
Zhao, M | 1 |
Qi, X | 1 |
Dai, K | 1 |
Bezard, E | 1 |
Soderstrom, KE | 1 |
O'Malley, JA | 1 |
Levine, ND | 1 |
Sortwell, CE | 1 |
Collier, TJ | 1 |
Steece-Collier, K | 1 |
Bean, BP | 1 |
Marchand, L | 1 |
5 other studies available for nimodipine and Parkinson Disease
Article | Year |
---|---|
Combining nanoscale magnetic nimodipine liposomes with magnetic resonance image for Parkinson's disease targeting therapy.
Topics: Animals; Blood-Brain Barrier; Drug Delivery Systems; Drug Liberation; Drug Stability; Humans; Liposo | 2017 |
Treating Parkinson's disease: preserve the spines! (Commentary on Soderstrom et al.).
Topics: Animals; Calcium Channel Blockers; Cell Transplantation; Dendritic Spines; Humans; Neurons, Efferent | 2010 |
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calcium Channel Blockers; Cell Transplantation; Den | 2010 |
Neurophysiology: stressful pacemaking.
Topics: Animals; Antiparkinson Agents; Calcium; Calcium Channels, L-Type; Disease Models, Animal; Disease Pr | 2007 |
[Treatment of essential tremor].
Topics: Anti-Anxiety Agents; Anti-Dyskinesia Agents; Botulinum Toxins; Humans; Hypnotics and Sedatives; Meth | 1995 |